Orforglipron
FOUNDAYO · LY3502970
A non-peptide GLP-1 receptor agonist formulated as a daily tablet rather than an injection, studied for glycemic control in type 2 diabetes and for weight management.
Tracking and educational reference only, on values you enter yourself. Not medical advice or a dosing recommendation.
Half-life
~29-49 h, oral. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Oral tablet; stored at room temperature in its original container per the label.
References
- FDA label: FOUNDAYO (NDA 220934)
- N Engl J Med 2023: daily oral orforglipron in adults with obesity
- N Engl J Med 2025: orforglipron for obesity treatment
Read the source
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.